Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 14/20 | 0.68 |
| ▸ | CXCR1 | P25024 | 10/20 | 0.68 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | TSPO | P30536 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6550018 | 0.92 | CXCR2 (0.64) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL27608153 | 0.86 | CXCR2 (0.68) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL6817256 | 0.85 | CXCR2 (0.49) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL6817254 | 0.85 | CXCR2 (0.49) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL6550790 | 0.85 | CXCR2 (0.67) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL6550053 | 0.81 | CXCR2 (1.00) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL6550011 | 0.80 | CXCR2 (0.63) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL6730340 | 0.80 | CXCR2 (0.65) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL13951815 | 0.79 | CXCR2 (0.76) | CXCR2CXCR1ADRB3TSPOSLC6A3 | |
| SCHEMBL7553831 | 0.79 | CXCR2 (1.00) | CXCR2CXCR1ADRB3TSPOSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | SMITHKLINE BEECHAM CORPORATION | 2004-06-10 | — | — | US | claimed |
| EP-1383488-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002079122-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | SMITHKLINE BEECHAM CORPORATION | 2004-06-10 | — | — | US | disclosed |
| EP-1383488-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002079122-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | COMT, BPHL, PNMT | CXCR2 2343/4885CXCR1 3658/4885ADRB3 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.